Patent application number | Description | Published |
20090011035 | Personal care composition - Stable personal care composition comprising from about 0.1% to about 15% of a non-emulsifying crosslinked siloxane elastomer; from about 0.1% to about 15% of an emulsifying crosslinked siloxane elastomer; from about 1% to about 40% of an elastomer solvent; less than 0.1% of a solidifying agent; an aqueous phase comprising from about 0.0001% to about 10%, by weight of the composition, of a hydrophilic colorant; whereupon application of shear force to the composition a visibly enhanced aqueous phase is visibly separated from the non-aqueous phase. | 01-08-2009 |
20090285768 | Compositions and Methods Incorporating Photocatalysts - The various embodiments provide a composition including an active material having functional groups capable of covalent attachment to a substrate in the presence of an acid or a base, a photocatalyst capable of generating an acid or a base upon exposure to light, and a vehicle. The compositions may also include surfactants, emulsifiers, oxidants, and other components. A method for treating a substrate is also disclosed. The method includes the steps of applying at least one active material having functional groups to the substrate, applying a photocatalyst to the substrate, and exposing the photocatalyst and the at least one active material to light for forming covalent attachments between the functional groups and constituent groups on the substrate. The compositions and methods described herein are useful in personal care product and consumer care product applications, for example. | 11-19-2009 |
20100247800 | Compositions and Methods Incorporating Photocatalysts - The present invention includes compositions comprising an active material having groups capable of covalent attachment to a substrate in the presence of an acid or a base, a photocatalyst capable of generating an acid or a base upon exposure to light, and a vehicle. Also included herein is a method for treating a substrate with these compositions. The method includes the steps of applying at least one active material having functional groups to the substrate, applying a photocatalyst to the substrate, and exposing the photocatalyst and the at least one active material to light for forming covalent attachments between the functional groups and constituent groups on the substrate. The compositions and methods described herein are useful in consumer care and personal care product applications. | 09-30-2010 |
20110114108 | Compositions and Methods Incorporating Photocatalysts - The present invention relates to a composition including an active material having groups capable of covalent attachment to a substrate in the presence of an acid or a base, a photocatalyst capable of generating an acid or a base upon exposure to light, and a vehicle. The active is a silicone polymer and/or a silicone oligomer, having a molecular weight higher than 1,000 grams/mole, and at least one organic functional group. The compositions may also include surfactants, emulsifiers, oxidants, and other components. A method for treating a substrate is also disclosed. The compositions and methods described herein are useful in personal care product and consumer care product applications. | 05-19-2011 |
20140120042 | Personal Care Compositions Comprising Self-Assembling Peptides - Disclosed herein are personal care compositions having at least one oligopeptide self-assembled into nanofibers or macrostructures, wherein the oligopeptide is 2-20 amino acids in length, and wherein the oligopeptide has at least one 0- to 10-amino-acid block of hydrophobic amino acids alternating with at least one 1- to 10-amino-acid block of hydrophilic amino acid residues. The composition may further include a dermatologically acceptable carrier and at least one cosmetic skin care agent. | 05-01-2014 |
Patent application number | Description | Published |
20080292720 | CHOLESTEROL-INTERACTING LAYERED PHYLLOSILICATES AND METHODS OF REDUCING HYPERCHOLESTEREMIA IN A MAMMAL - Layered phyllosilicates are useful for adsorbing and/or binding to cholesterol and, thereby, reducing blood cholesterol in a patient. Accordingly, provided herein is a method of reducing hypercholesteremia in a mammal comprising administering to said mammal a protonated and at least partially exfoliated layered phyllosilicate material alone and in combination with other cholesterol-reducing agents in an amount effective to reduce hypercholesteremia in said mammal. | 11-27-2008 |
20080317844 | Pharmaceutical Delivery Systems for Hydrophobic Drugs and Compositions Compositions Comprising Same - A drug delivery system for oral administration of hydrophobic drugs with enhanced and extended absorption and improved pharmacokinetics is provided. In one embodiment, formulations comprising testosterone and testosterone esters, e.g., testosterone palmitate, are disclosed. Methods of treating a hormone deficiency or effecting male contraception with the inventive formulations are also provided. | 12-25-2008 |
20100272769 | Virus-, Bacteria-, and Fungi-Interacting Layered Phyllosilicates and Methods of Use - Layered phyllosilicates are useful for adsorbing and/or binding to and, thereby, inactivating viruses, bacteria and fungi. Accordingly, provided herein are methods of inactivating a virus, bacteria or fungus and methods of treating a viral, bacterial or fungal infection. Methods of delivering a therapeutic agent to a mammalian subject and methods of inactivating a virus in the gastrointestinal tract of an animal are also provided. | 10-28-2010 |
20110086069 | PHARMACEUTICAL FORMULATIONS OF NITRITE AND USES THEREOF - The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO | 04-14-2011 |
20110251167 | ORAL TESTOSTERONE ESTER FORMULATIONS AND METHODS OF TREATING TESTOSTERONE DEFICIENCY COMPRISING SAME - A pharmaceutical formulation of testosterone undecanoate is provided. Methods of treating a testosterone deficiency or its symptoms with the inventive formulations are also provided. | 10-13-2011 |
20120309731 | ORAL TESTOSTERONE ESTER FORMULATIONS AND METHODS OF TREATING TESTOSTERONE DEFICIENCY COMPRISING SAME - A pharmaceutical formulation of testosterone undecanoate is provided. Methods of treating a testosterone deficiency or its symptoms with the inventive formulations are also provided. | 12-06-2012 |
20130022674 | PHARMACEUTICAL DELIVERY SYSTEMS FOR HYDROPHOBIC DRUGS AND COMPOSITIONS COMPRISING SAME - A drug delivery system for oral administration of hydrophobic drugs with enhanced and extended absorption and improved pharmacokinetics is provided. In one embodiment, formulations comprising testosterone and testosterone esters, e.g., testosterone palmitate, are disclosed. Methods of treating a hormone deficiency or effecting male contraception with the inventive formulations are also provided. | 01-24-2013 |
20140011789 | PHARMACEUTICAL DELIVERY SYSTEMS FOR HYDROPHOBIC DRUGS AND COMPOSITIONS COMPOSITIONS COMPRISING SAME - A drug delivery system for oral administration of hydrophobic drugs with enhanced and extended absorption and improved pharmacokinetics is provided. In one embodiment, formulations comprising testosterone and testosterone esters, e.g., testosterone palmitate, are disclosed. Methods of treating a hormone deficiency or effecting male contraception with the inventive formulations are also provided. | 01-09-2014 |
20140249124 | PHARMACEUTICAL DELIVERY SYSTEMS FOR HYDROPHOBIC DRUGS AND COMPOSITIONS COMPRISING SAME - A drug delivery system for oral administration of hydrophobic drugs with enhanced and extended absorption and improved pharmacokinetics is provided. In one embodiment, formulations comprising testosterone and testosterone esters, e.g., testosterone palmitate, are disclosed. Methods of treating a hormone deficiency or effecting male contraception with the inventive formulations are also provided. | 09-04-2014 |
20140274986 | ORAL TESTOSTERONE ESTER FORMULATIONS AND METHODS OF TREATING TESTOSTERONE DEFICIENCY COMPRISING SAME - A pharmaceutical formulation of testosterone undecanoate is provided. Methods of treating a testosterone deficiency or its symptoms with the inventive formulations are also provided. | 09-18-2014 |
20140296199 | PHARMACEUTICAL DELIVERY SYSTEMS FOR HYDROPHOBIC DRUGS AND COMPOSITIONS COMPOSITIONS COMPRISING SAME - A drug delivery system for oral administration of hydrophobic drugs with enhanced and extended absorption and improved pharmacokinetics is provided. In one embodiment, formulations comprising testosterone and testosterone esters, e.g., testosterone palmitate, are disclosed. Methods of treating a hormone deficiency or effecting male contraception with the inventive formulations are also provided. | 10-02-2014 |
20140303129 | METHODS OF TREATING TESTOSTERONE DEFICIENCY - Methods of treating a testosterone deficiency or its symptoms with a pharmaceutical formulation of testosterone esters are provided. The methods are designed toprovide optimum serum testosterone levels over an extended period. | 10-09-2014 |